Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | PAM | P19021 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3191369 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104018 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL168910 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL560522 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104054 | 0.99 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL5227791 | 0.96 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL821391 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL739576 | 0.92 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3204051 | 0.89 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1261121 | 0.88 | MEN1 (0.39) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101744740-B | Process for depigmenting keratin materials using dithiolane compounds | OREAL | 2014-01-08 | — | — | CN | disclosed |
| CN-101744740-A | Process for depigmenting keratin materials using dithiolane compounds | OREAL | 2010-06-23 | — | — | CN | disclosed |
| CN-1282644-C | Indane or indoline derivative | LUNDBECK & CO AS H (DK) | 2006-11-01 | — | — | CN | disclosed |
| CN-1244558-C | 1,2-indane or indoline derivative | LUNDBECK & CO AS H (DK) | 2006-03-08 | — | — | CN | disclosed |
| CN-1515551-A | 1,2-indane or indoline derivative | H.¡�±�������˾ | 2004-07-28 | — | — | CN | disclosed |
| CN-1495165-A | Indane or indoline derivative | H.¡�±�������˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1146556-C | 1, 2-indane or indoline derivative and preparation method and application thereof | H.¡�±�������˾ | 2004-04-21 | — | — | CN | disclosed |
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| US-6153641-A | Pharmaceutically active compounds | ASTRA AKTIEBOLAG (SE) | 2000-11-28 | — | — | US | disclosed |
| CN-1246117-A | 1, 2-indane or indoline derivatives | LUNDBECK & CO AS H (DK) | 2000-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MEN1 1916/4885MAPT 2009/4885KMT2A 2394/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MEN1 1916/4885MAPT 2009/4885KMT2A 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.